Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be ...

An implantable vagus nerve stimulation device yielded an ACR20 response rate of more than 52% at 12 months in patients with rheumatoid arthritis, according to findings published in Nature ...

Yes in God’s Backyard, a zonal transit system, MLB to Raleigh; here are the big ideas at-large candidates for Raleigh City ...

Share prices at Publicis Groupe, Omnicom, Havas and WPP took a dive during trading yesterday (3 February), with analysts attributing the decline to the threat of disruptive new AI tools that could ...

The aerial-accessed service has a fast-dwindling audience but when exactly to switch the platform off is proving highly divisive ...

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...

Evodrop received a 2025 Global Recognition Award for its patented bio-based malic acid limescale solution, which has been independently ...

The crossover hits stacking Grammy nods this year have little in common with the culture that birthed them — but they're ...

India's Economic Survey highlights the need for financial regulators to balance growth and stability amid global ...

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By ...